[1]邵毅,温佳怡,令倩.年龄相关性黄斑变性诊断与治疗规范：2022年英国皇家眼科医学会指南解读[J].眼科新进展,2023,43(2):085-88.[doi:10.13389/j.cnki.rao.2023.0017]
　SHAO Yi,WEN Jiayi,LING Qian.Norms for diagnosis and treatment of age-related macular degeneration: an analysis of the 2022 Guideline of the Royal College of Ophthalmologists[J].Recent Advances in Ophthalmology,2023,43(2):085-88.[doi:10.13389/j.cnki.rao.2023.0017]
点击复制

年龄相关性黄斑变性诊断与治疗规范：2022年英国皇家眼科医学会指南解读/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
43卷
期数:
2023年2期
页码:
085-88
栏目:
述评
出版日期:
2023-02-05

文章信息/Info

Title:
Norms for diagnosis and treatment of age-related macular degeneration: an analysis of the 2022 Guideline of the Royal College of Ophthalmologists
作者:
邵毅; 温佳怡; 令倩
330006　江西省南昌市，南昌大学第一附属医院眼科
Author(s):
SHAO Yi; WEN Jiayi;  LING Qian
Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China
关键词:
年龄相关性黄斑变性; 指南; 治疗; 诊断
Keywords:
age-related macular degeneration;  guideline;  treatment;  diagnosis
分类号:
R774
DOI:
10.13389/j.cnki.rao.2023.0017
文献标志码:
A
摘要:
年龄相关性黄斑变性(AMD),又称老年性黄斑变性，为黄斑区结构的衰老性改变，主要由视网膜色素上皮细胞和视网膜退行性病变引起，患者会出现不可逆性中心视力下降、视物变形。英国皇家眼科医学会发布了最新的AMD指南，对AMD的定义、分类、诊断和治疗等做了详细介绍。本文将对该指南进行全面解读，旨在为广大医务工作者进一步提高AMD的诊断和治疗水平提供参考，以期更好地服务于广大眼病患者。
Abstract:
Age-related macular degeneration (AMD), also known as senile macular degeneration, is an aging change in the structure of the macular area, which is mainly caused by degeneration of retinal pigment epithelial cells and retina.Patients with this disease suffer from irreversible central vision loss and visual deformation. The Royal College of Ophthalmologists published the latest guidelines for AMD detailing the definition, classification, diagnosis and treatment of AMD. In this article, a comprehensive analysis is made on the guidelines, with the aim of improving the diagnosis and treatment of AMD and providing better services for patients with eye diseases.

参考文献/References:

［1］　WONG W L,SU X Y,LI X,CHEUNG C M,KLEIN R,CHENG C Y,et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040:a systematic review and meta-analysis［J］.Lancet Glob Health,2014,2(2):e106-116.
［2］　KLEIN R,PETO T,BIRD A,VANNEWKIRK M R.The epidemiology of age-related macular degeneration［J］.Am J Ophthalmol,2004,137(3):486-495.
［3］　MITCHELL P,LIEW G,GOPINATH B,WONG T Y.Age-related macular degeneration［J］.Lancet,2018,392(10153):1147-1159.
［4］　火成栋,张文芳,杨义,李玉婷,眼科辅助检查在年龄相关性黄斑变性中的应用 ［J］.国际眼科杂志,2018,18(1):84-88.
HUO C D,ZHANG W F,YANG Y,LI Y T.Appilication of ophthalmic auxiliary examination in age-related macular degeneration［J］.Int Eye Sci,2018,18(1):84-88.
［5］　GUALINO V,TADAYONI R,COHEN S Y,ERGINAY A,FAJNKUCHEN F,HAOUCHINE B,et al.Optical coherence tomography,fluorescein angiography,and diagnosis of choroidal neovascularization in age-related macular degeneration［J］.Retina,2019,39(9):1664-1671.
［6］　GONG J,YU S,GONG Y,WANG F,SUN X.The diagnostic accuracy of optical coherence tomography angiography for neovascular age-related macular degeneration:a comparison with fundus fluorescein angiography［J］.J Ophthalmol,2016,2016:7521478.
［7］　PAPADOPOULOS Z.Recent developments in the treatment of wet age-related macular degeneration［J］.Curr Med Sci,2020,40(5):851-857.
［8］　CHANDRA S,MCKIBBIN M,MAHMOOD S,DOWNEY L,BARNES B,SIVAPRASAD S.The Royal College of Ophthalmologists commissioning guidelines on age macular degeneration:executive summary［J］.Eye,2022,36(11):2078-2083.
［9］　Age-Related Eye Disease Study Research Group.A randomized,placebo-controlled,clinical trial of high-dose supplementation with vitamins C and E,beta carotene,and zinc for age-related macular degeneration and vision loss:AREDS report No.8［J］.Arch Ophthalmol,2001,119(10):1417-1436.
［10］　MA L,DOU H L,WU Y Q,HUANG Y M,HUANG Y B,XU X R,et al.Lutein and zeaxanthin intake and the risk of age-related macular degeneration:a systematic review and meta-analysis［J］.Br J Nutr,2012,107(3):350-359.
［11］　WU J,SUN X.Complement system and age-related macular degeneration:drugs and challenges［J］.Drug Des Devel Ther,2019,13:2413-2425.
［12］　KASHANI A H.Stem cell-derived retinal pigment epithelium transplantation in age-related macular degeneration:recent advances and challenges［J］.Curr Opin Ophthalmol,2022,33(3):211-218.
［13］　INTARTAGLIA D,GIAMUNDO G,CONTE I.Autophagy in the retinal pigment epithelium:a new vision and future challenges［J］.FEBS J,2022,289(22)：7199-7212.
［14］　LEE K S,LIN S,COPLAND D A,DICK A D,LIU J.Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration［J］.J Neuroinflammation,2021,18(1):32.
［15］　WYKOFF C C,ROSENFELD P J,WAHEED N K,SINGH R P,RONCA N,SLAKTER J S,et al.Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy［J］.Ophthalmology,2021,128(9):1325-1336.
［16］　LI J,ZHANG H,SUN P,GU F,LIU Z L.Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients［J］.Int J Ophthalmol,2013,6(2):169-173.
［17］　HOLASH J,DAVIS S,PAPADOPOULOS N,CROLL S D,HO L,RUSSELL M,et al.VEGF-Trap:a VEGF blocker with potent antitumor effects［J］.Proc Natl Acad Sci U S A,2002,99(17):11393-11398.
［18］　HAMID M A,ABDELFATTAH N S,SALAMZADEH J,ABDELAZIZ S T A,SABRY A M,MOURAD K M,et al.Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab［J］.Int J Retina Vitreous,2021,7(1):26.
［19］　CHANG A A,LI H,BROADHEAD G K,HONG T,SCHLUB T E,WIJEYAKUMAR W,et al.Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration［J］.Ophthalmology,2014,121(1):188-192.
［20］　FASSNACHT-RIEDERLE H,BECKER M,GRAF N,MICHELS S.Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD［J］.Graefes Arch Clin Exp Ophthalmol,2014,252(11):1705-1709.
［21］　MARKHAM A.Brolucizumab:first approval［J］.Drugs,2019,79(18):1997-2000.
［22］　HOLZ F G,DUGEL P U,WEISSGERBER G,HAMILTON R,SILVA R,BANDELLO F,et al.Single-chain antibody fragment VEGF Inhibitor RTH258 for neovascular age-related macular degeneration:a randomized controlled study［J］.Ophthalmology,2016,123(5):1080-1089.
［23］　MOZETIC V,PACHECO R L,LATORRACA C O C,LEE F,GOMES J V B,RIERA R.What do Cochrane systematic reviews say about interventions for age-related macular degeneration?［J］.Sao Paulo Med J,2019,137(6):530-542.
［24］　PANDE G S,TIDAKE P.Laser treatment modalities for diabetic retinopathy［J］.Cureus,2022,14(10):e30024.
［25］　GRZYBOWSKI A,MARKEVICIUTE A,ZEMAITIENE R.Treatment of macular edema in vascular retinal diseases:a 2021 update［J］.J Clin Med,2021,10(22):5300.
［26］　AL-ZAMIL W M,YASSIN S A.Recent developments in age-related macular degeneration:a review［J］.Clin Interv Aging,2017,12:1313-1330.
［27］　SHAO J,CHOUDHARY M M,SCHACHAT A P.Neovascular age-related macular degeneration［J］.Dev Ophthalmol,2016,55:125-136.
［28］　ROFAGHA S,BHISITKUL R B,BOYER D S,SADDA S R,ZHANG K.Seven-year outcomes in ranibizumab-treated patients in anchor,marina,and horizon:a multicenter cohort study (SEVEN-UP)［J］.Ophthalmology,2013,120(11):2292-2299.
［29］　COPLAND D A,THEODOROPOULOU S,LIU J,DICK A D.A perspective of AMD through the eyes of immunology［J］.Invest Ophthalmol Vis Sci,2018,59(4):amd83-amd92.
［30］　LUDWIG P E,FREEMAN S C,JANOT A C.Novel stem cell and gene therapy in diabetic retinopathy,age related macular degeneration,and retinitis pigmentosa［J］.Int J Retina Vitreous,2019,5:7.
［31］　DENG Y,QIAO L,DU M,QU C,WAN L,LI J,et al.Age-related macular degeneration:epidemiology,genetics,pathophysiology,diagnosis,and targeted therapy［J］.Genes Dis,2022,9(1):62-79.
［32］　BAKRI S J,THORNE J E,HO A C,EHLERS J P,SCHOENBERGER S D,YEH S,et al.Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration:a report by the American academy of ophthalmology［J］.Ophthalmology,2019,126(1):55-63.
［33］　MERANI R,HUNYOR A P.Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection:a comprehensive review［J］.Int J Retina Vitreous,2015,1:9.
［34］　BANISTER K,COOK J A,SCOTLAND G,AZUARA-BLANCO A,GOULO B,HEIMANN H,et al.Non-invasive testing for early detection of neovascular macular degeneration in unaffected second eyes of older adults:EDNA diagnostic accuracy study［J］.Health Technol Assess,2022,26(8):1-142.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[5]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[6]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[7]陆秉文 吴星伟.光动力疗法治疗年龄相关性黄斑变性的研究进展[J].眼科新进展,2013,33(4):000.
[8]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[9]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[10]金鑫,张红.MicroRNA在年龄相关性黄斑变性发病中的作用[J].眼科新进展,2014,34(8):787.[doi:10.13389/j.cnki.rao.2014.0218]
　JIN Xin,ZHANG Hong.Role of microRNA in pathogenesis of agerelated macular degeneration[J].Recent Advances in Ophthalmology,2014,34(2):787.[doi:10.13389/j.cnki.rao.2014.0218]
[11]邵毅,周琼.年龄相关性黄斑变性诊断与治疗规范——2018年英国专家共识解读[J].眼科新进展,2019,39(11):1001.[doi:10.13389/j.cnki.rao.2019.0229]
　SHAO Yi,ZHOU Qiong.Diagnosis and treatment of age-related macular degeneration:An interpretation of British National Institute for Health and Care Excellence (NICE) in 2018[J].Recent Advances in Ophthalmology,2019,39(2):1001.[doi:10.13389/j.cnki.rao.2019.0229]

备注/Memo

备注/Memo:
国家自然科学基金项目（编号:82160195）；中央引导地方科技发展资金项目（编号:20211ZDG02003）
更新日期/Last Update: 2023-02-05